Takeda’s Entyvio (vedolizumab) has been shortlisted for the prestigious Prix Galien UK 2016 Innovation Products Award. Entyvio is indicated for the treatment of adult patients with inflammatory bowel disease.
Craig Adkins, Business Unit Director for Entyvio said: “Entyvio demonstrates Takeda’s commitment to innovation and we are delighted to be shortlisted for such a prestigious award. It is a testament to the hard work of all involved that we are already being recognised for making significant advances”.
Takeda’s Entyvio (vedolizumab) has been shortlisted for the prestigious Prix Galien UK 2016 Innovation Products Award. Entyvio is indicated for the treatment of adult patients with inflammatory bowel disease.
Craig Adkins, Business Unit Director for Entyvio said: “Entyvio demonstrates Takeda’s commitment to innovation and we are delighted to be shortlisted for such a prestigious award. It is a testament to the hard work of all involved that we are already being recognised for making significant advances”.
Prix Galien 2016 has attracted a record number of entries, with Entyvio competing against six other medicines in the Innovation Products category. The awards will take place on 21 September, 2016 at the House of Commons, London.
The Prix Galien Awards were established to recognise and highlight significant steps forward in pharmaceutical advancement. The awards aim to celebrate the outstanding efforts made to improve human conditions through the development of novel, high-value medicines. They are the only independent awards of their kind, judged by highly respected healthcare leaders and specialists.
